Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.

Dolores IslaMarta Lopez-BreaMaría EspinosaNatalia ArrabalDiego Pérez-ParenteDavid CarcedoReyes Bernabé-Caro

Published in: Cost effectiveness and resource allocation : C/E (2023)

The cost-effectiveness analysis, comparing the two cut-off of IMpower110, shows that atezolizumab provides similar health gains to pembrolizumab but at a lower cost for the first-line treatment of metastasic NSCLC patients in Spain.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
end stage renal disease
healthcare
ejection fraction
public health
chronic kidney disease
mental health
prognostic factors
peritoneal dialysis
small cell lung cancer
tyrosine kinase
social media